Cargando…

Light-Control over Casein Kinase 1δ Activity with Photopharmacology: A Clear Case for Arylazopyrazole-Based Inhibitors

Protein kinases are responsible for healthy cellular processes and signalling pathways, and their dysfunction is the basis of many pathologies. There are numerous small molecule inhibitors of protein kinases that systemically regulate dysfunctional signalling processes. However, attaining selectivit...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulte, Albert M., Kolarski, Dušan, Sundaram, Vidya, Srivastava, Ashutosh, Tama, Florence, Feringa, Ben L., Szymanski, Wiktor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140716/
https://www.ncbi.nlm.nih.gov/pubmed/35628143
http://dx.doi.org/10.3390/ijms23105326
_version_ 1784715166247550976
author Schulte, Albert M.
Kolarski, Dušan
Sundaram, Vidya
Srivastava, Ashutosh
Tama, Florence
Feringa, Ben L.
Szymanski, Wiktor
author_facet Schulte, Albert M.
Kolarski, Dušan
Sundaram, Vidya
Srivastava, Ashutosh
Tama, Florence
Feringa, Ben L.
Szymanski, Wiktor
author_sort Schulte, Albert M.
collection PubMed
description Protein kinases are responsible for healthy cellular processes and signalling pathways, and their dysfunction is the basis of many pathologies. There are numerous small molecule inhibitors of protein kinases that systemically regulate dysfunctional signalling processes. However, attaining selectivity in kinase inhibition within the complex human kinome is still a challenge that inspires unconventional approaches. One of those approaches is photopharmacology, which uses light-controlled bioactive molecules to selectively activate drugs only at the intended space and time, thereby avoiding side effects outside of the irradiated area. Still, in the context of kinase inhibition, photopharmacology has thus far been rather unsuccessful in providing light-controlled drugs. Here, we present the discovery and optimisation of a photoswitchable inhibitor of casein kinase 1δ (CK1δ), important for the control of cell differentiation, circadian rhythm, DNA repair, apoptosis, and numerous other signalling processes. Varying the position at which the light-responsive azobenzene moiety has been introduced into a known CK1δ inhibitor, LH846, revealed the preferred regioisomer for efficient photo-modulation of inhibitory activity, but the photoswitchable inhibitor suffered from sub-optimal (photo)chemical properties. Replacement of the bis-phenyl azobenzene group with the arylazopyrazole moiety yielded a superior photoswitch with very high photostationary state distributions, increased solubility and a 10-fold difference in activity between irradiated and thermally adapted samples. The reasons behind those findings are explored with molecular docking and molecular dynamics simulations. Results described here show how the evaluation of privileged molecular architecture, followed by the optimisation of the photoswitchable unit, is a valuable strategy for the challenging design of the photoswitchable kinase inhibitors.
format Online
Article
Text
id pubmed-9140716
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91407162022-05-28 Light-Control over Casein Kinase 1δ Activity with Photopharmacology: A Clear Case for Arylazopyrazole-Based Inhibitors Schulte, Albert M. Kolarski, Dušan Sundaram, Vidya Srivastava, Ashutosh Tama, Florence Feringa, Ben L. Szymanski, Wiktor Int J Mol Sci Article Protein kinases are responsible for healthy cellular processes and signalling pathways, and their dysfunction is the basis of many pathologies. There are numerous small molecule inhibitors of protein kinases that systemically regulate dysfunctional signalling processes. However, attaining selectivity in kinase inhibition within the complex human kinome is still a challenge that inspires unconventional approaches. One of those approaches is photopharmacology, which uses light-controlled bioactive molecules to selectively activate drugs only at the intended space and time, thereby avoiding side effects outside of the irradiated area. Still, in the context of kinase inhibition, photopharmacology has thus far been rather unsuccessful in providing light-controlled drugs. Here, we present the discovery and optimisation of a photoswitchable inhibitor of casein kinase 1δ (CK1δ), important for the control of cell differentiation, circadian rhythm, DNA repair, apoptosis, and numerous other signalling processes. Varying the position at which the light-responsive azobenzene moiety has been introduced into a known CK1δ inhibitor, LH846, revealed the preferred regioisomer for efficient photo-modulation of inhibitory activity, but the photoswitchable inhibitor suffered from sub-optimal (photo)chemical properties. Replacement of the bis-phenyl azobenzene group with the arylazopyrazole moiety yielded a superior photoswitch with very high photostationary state distributions, increased solubility and a 10-fold difference in activity between irradiated and thermally adapted samples. The reasons behind those findings are explored with molecular docking and molecular dynamics simulations. Results described here show how the evaluation of privileged molecular architecture, followed by the optimisation of the photoswitchable unit, is a valuable strategy for the challenging design of the photoswitchable kinase inhibitors. MDPI 2022-05-10 /pmc/articles/PMC9140716/ /pubmed/35628143 http://dx.doi.org/10.3390/ijms23105326 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schulte, Albert M.
Kolarski, Dušan
Sundaram, Vidya
Srivastava, Ashutosh
Tama, Florence
Feringa, Ben L.
Szymanski, Wiktor
Light-Control over Casein Kinase 1δ Activity with Photopharmacology: A Clear Case for Arylazopyrazole-Based Inhibitors
title Light-Control over Casein Kinase 1δ Activity with Photopharmacology: A Clear Case for Arylazopyrazole-Based Inhibitors
title_full Light-Control over Casein Kinase 1δ Activity with Photopharmacology: A Clear Case for Arylazopyrazole-Based Inhibitors
title_fullStr Light-Control over Casein Kinase 1δ Activity with Photopharmacology: A Clear Case for Arylazopyrazole-Based Inhibitors
title_full_unstemmed Light-Control over Casein Kinase 1δ Activity with Photopharmacology: A Clear Case for Arylazopyrazole-Based Inhibitors
title_short Light-Control over Casein Kinase 1δ Activity with Photopharmacology: A Clear Case for Arylazopyrazole-Based Inhibitors
title_sort light-control over casein kinase 1δ activity with photopharmacology: a clear case for arylazopyrazole-based inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140716/
https://www.ncbi.nlm.nih.gov/pubmed/35628143
http://dx.doi.org/10.3390/ijms23105326
work_keys_str_mv AT schultealbertm lightcontrolovercaseinkinase1dactivitywithphotopharmacologyaclearcaseforarylazopyrazolebasedinhibitors
AT kolarskidusan lightcontrolovercaseinkinase1dactivitywithphotopharmacologyaclearcaseforarylazopyrazolebasedinhibitors
AT sundaramvidya lightcontrolovercaseinkinase1dactivitywithphotopharmacologyaclearcaseforarylazopyrazolebasedinhibitors
AT srivastavaashutosh lightcontrolovercaseinkinase1dactivitywithphotopharmacologyaclearcaseforarylazopyrazolebasedinhibitors
AT tamaflorence lightcontrolovercaseinkinase1dactivitywithphotopharmacologyaclearcaseforarylazopyrazolebasedinhibitors
AT feringabenl lightcontrolovercaseinkinase1dactivitywithphotopharmacologyaclearcaseforarylazopyrazolebasedinhibitors
AT szymanskiwiktor lightcontrolovercaseinkinase1dactivitywithphotopharmacologyaclearcaseforarylazopyrazolebasedinhibitors